AZD 4635

Drug Profile

AZD 4635

Alternative Names: AZD-4635; HTL 1071

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heptares Therapeutics
  • Developer AstraZeneca; Heptares Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Cancer

Most Recent Events

  • 08 May 2018 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT03381274)
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 21 Dec 2017 MedImmune plans a phase Ib/II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and South Korea (D6070C00004; NCT03381274)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top